Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Nucl Med Biol. 2010 Apr;37(3):335-45. doi: 10.1016/j.nucmedbio.2009.12.010.
[(11)C]Loperamide and [(11)C]N-desmethyl-loperamide ([(11)C]dLop) have been proposed as radiotracers for imaging brain P-glycoprotein (P-gp) function. A major route of [(11)C]loperamide metabolism is N-demethylation to [(11)C]dLop. We aimed to test whether inhibition of CYP3A4 with ketoconazole might reduce the metabolism of [(11)C]loperamide and [(11)C]dLop in mice, and thereby improve the quality of these radiotracers.
Studies were performed in wild-type and P-gp knockout (mdr-1a/b -/-) mice. During each of seven study sessions, one pair of mice, comprising one wild-type and one knockout mouse, was pretreated with ketoconazole (50 mg/kg, ip), while another such pair was left untreated. Mice were sacrificed at 30 min after injection of [(11)C]loperamide or [(11)C]dLop. Whole brain and plasma samples were measured for radioactivity and analyzed with radio-high-performance liquid chromatography.
Ketoconazole increased the plasma concentrations of [(11)C]loperamide and its main radiometabolite, [(11)C]dLop, by about twofold in both wild-type and knockout mice, whereas the most polar radiometabolite was decreased threefold. Furthermore, ketoconazole increased the brain concentrations of [(11)C]loperamide and the radiometabolite [(11)C]dLop by about twofold in knockout mice, and decreased the brain concentrations of the major and most polar radiometabolite in wild-type and knockout mice by 82% and 49%, respectively. In contrast, ketoconazole had no effect on plasma and brain distribution of administered [(11)C]dLop and its radiometabolites in either wild-type or knockout mice, except to increase the low plasma [(11)C]dLop concentration. The least polar radiometabolite of [(11)C]dLop was identified with LC-MS(n) as the N-hydroxymethyl analog of [(11)C]dLop and this also behaved as a P-gp substrate.
In this study, ketoconazole (50 mg/kg, ip) proved partially effective for inhibiting the N-demethylation of [(11)C]loperamide in mouse in vivo but had relatively smaller or no effect on [(11)C]dLop.
[(11)C]洛哌丁胺和[(11)C]去甲基-洛哌丁胺([(11)C]dLop)已被提议作为成像脑 P 糖蛋白(P-gp)功能的放射性示踪剂。[(11)C]洛哌丁胺的主要代谢途径是 N-去甲基化为[(11)C]dLop。我们旨在测试酮康唑抑制 CYP3A4 是否会减少小鼠中[(11)C]洛哌丁胺和[(11)C]dLop 的代谢,从而提高这些放射性示踪剂的质量。
在野生型和 P-糖蛋白敲除(mdr-1a/b -/-)小鼠中进行了研究。在七次研究期间的每一次,一对包括一只野生型和一只敲除型小鼠的小鼠,用酮康唑(50 mg/kg,ip)预处理,而另一对则不进行预处理。在注射[(11)C]洛哌丁胺或[(11)C]dLop 后 30 分钟处死小鼠。测量全脑和血浆样品的放射性,并进行放射性高效液相色谱分析。
酮康唑使野生型和敲除型小鼠的血浆中[(11)C]洛哌丁胺及其主要放射性代谢物[(11)C]dLop 的浓度增加约两倍,而最极性的放射性代谢物则减少三倍。此外,酮康唑使敲除型小鼠脑内[(11)C]洛哌丁胺和放射性代谢物[(11)C]dLop 的浓度增加约两倍,并使野生型和敲除型小鼠的主要和最极性放射性代谢物的脑浓度分别降低 82%和 49%。相比之下,酮康唑对野生型和敲除型小鼠给予的[(11)C]dLop 和其放射性代谢物的血浆和脑分布没有影响,除了增加低血浆[(11)C]dLop 浓度外。[(11)C]dLop 的最不极性放射性代谢物通过 LC-MS(n)鉴定为[(11)C]dLop 的 N-羟甲基类似物,它也表现为 P-gp 底物。
在这项研究中,酮康唑(50 mg/kg,ip)在体内部分有效抑制了小鼠中[(11)C]洛哌丁胺的 N-去甲基化,但对[(11)C]dLop 的影响相对较小或没有。